Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: The standard of care? Journal Article

  

Authors:	Zumsteg, Z. S.; Zelefsky, M. J.
Article Title:	Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: The standard of care?
Abstract:	What is the best way to manage patients with intermediate-risk prostate cancer? One of the most controversial aspects of treatment is the role of short-term androgen deprivation therapy in combination with definitive radiotherapy. In two randomised trials of patients with mostly intermediate-risk prostate cancer, increased overall survival was reported when short-term androgen deprivation therapy was added to radiotherapy. However, radiation doses in these studies were far below the current standard of care. This limitation, in combination with the heterogeneous nature of the cancers classified as intermediate risk, has complicated the application of these trial results to modern clinical practice. In this Review, we discuss clinical evidence for and against use of short-term androgen deprivation therapy with dose-escalated radiotherapy for patients with intermediate-risk prostate cancer. © 2012 Elsevier Ltd.
Keywords:	immunohistochemistry; cancer survival; treatment outcome; treatment response; aged; disease-free survival; middle aged; fracture; survival rate; fatigue; review; side effect; treatment duration; united states; adjuvant therapy; cancer adjuvant therapy; radiation dose; combined modality therapy; neoplasm staging; anemia; drug administration schedule; radiotherapy; libido disorder; randomized controlled trials as topic; risk assessment; dose-response relationship, radiation; prostate cancer; prostatic neoplasms; depression; sexual dysfunction; prostatectomy; diabetes mellitus; androgen antagonists; brachytherapy; metabolic syndrome x; neoplasm invasiveness; hot flush; osteoporosis; radiotherapy, conformal; external beam radiotherapy; antiandrogen; cancer classification; dose fractionation; androgen deprivation therapy; gynecomastia; radiosensitization; muscle atrophy; randomized controlled trial (topic); phase 3 clinical trial (topic); mood change; weight change; dose escalated radiotherapy; intermediate risk prostate cancer
Journal Title:	Lancet Oncology
Volume:	13
Issue:	6
ISSN:	1470-2045
Publisher:	Elsevier Science, Inc.
Date Published:	2012-06-01
Start Page:	e259
End Page:	e269
Language:	English
DOI:	10.1016/s1470-2045(12)70084-0
PROVIDER:	scopus
PUBMED:	22652234
DOI/URL:	http://www.scopus.com/inward/record.url?eid=2-s2.0-84861555230&partnerID=40&md5=c3811a92b92e42d01f1ce81b2ae3a5d5
Notes:	--- - "Export Date: 2 July 2012" - "CODEN: LOANB" - "Source: Scopus"

https://synapse.mskcc.org/synapse/works/has_related_data_chk/29221